Cognitive Enhancement in Bipolar Disorder: A Double-Blind, Randomized Controlled Trial Utilizing a Novel DTI-Guided Multimodal Neuro-stimulation Protocol ========================================================================================================================================================= * Minmin Wang * Xiaomei Zhang * Hetong Zhou * Qianfeng Chen * Qiqi Tong * Qiai Han * Xudong Zhao * Dandan Wang * Jianbo Lai * Hongjian He * Shaomin Zhang * Shaohua Hu ## Abstract **Background** Traditional neuromodulation strategies for enhancing cognitive abilities in bipolar disorder (BD) patients have shown promise, yet there remains a need for novel intervention modalities to improve therapeutic outcomes. **Methods** This study introduces a novel multi-modal neuro-stimulaton (MNS) protocol using individualized DTI data to identify fiber tracts between the DLPFC and dACC. The highest structural connectivity point is selected as the individualized stimulation target, which is targeted using a combination of optimized tACS and robot-assisted navigated rTMS. A double-blind randomized controlled trial (Trial registration number: [NCT05964777](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05964777&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F27%2F2024.07.25.24311037.atom)) was conducted to investigate the clinical efficacy of this innovative neuromodulation approach on cognitive abilities in BD patients. One hundred BD patients were randomly assigned to four groups: Group A (Active tACS-Active rTMS (MNS Protocol)), Group B (Sham tACS-Active rTMS), Group C (Active tACS-Sham rTMS), and Group D (Sham tACS-Sham rTMS). Participants underwent 15 sessions over three weeks. Cognitive assessments (THINC integrated tool) were conducted at baseline (Week 0), post-treatment (Week 3), and follow-up (Week 8). **Results** Sixty-six participants completed all 15 sessions. Group A (MNS Protocol) showed superior improvements in Spotter CRT, TMT, and DSST scores compared to other groups at Week 3, with sustained cognitive enhancement in Spotter CRT at Week 8 (*P* < 0.01). Only Group A exhibited significant activation in the left frontal region post-MNS intervention. The novel MNS protocol was well tolerated, with no significant side effects observed. **Conclusions** DTI-guided multimodal neuro-stimulation mode significantly improves cognitive impairments and is safe for BD patients. **Highlights** 1. Using DTI-derived neural fiber density to determine the target sites for tACS and rTMS in patients with bipolar disorder. 2. Combining sequential tACS and rTMS to significantly improve cognitive function in the bipolar disorder patients. 3. Utilizing individually optimized tACS and robot-assisted navigated rTMS to achieve high-precision transcranial stimulation. Keywords * Diffusion Tensor Imaging * Transcranial Alternating Current Stimulation * Repetitive Transcranial Magnetic Stimulation * Electric Field * Individualization ## 1. Introduction Bipolar disorder (BD) is a complex and debilitating psychiatric disease characterized by recurrent episodes of mania and depression1. Patients with BD may suffer from widespread cognitive impairments, including deficits in attention, learning, memory, and executive functions, leading to significant occupational and social dysfunction2. Current treatments for cognitive impairment in BD, including pharmacological, psychological, and behavioral therapies, are constrained by heterogeneous treatment outcomes, slow symptom relief, and associated risks and side effects3,4. These limitations highlight the need for innovative therapeutic approaches to improve the cognitive functions5,6. Non-invasive neuromodulation, such as transcranial electrical stimulation (tES) and repetitive transcranial magnetic stimulation (rTMS), has emerged as promising methods for cognitive enhancement in patients7,8. Transcranial alternating current stimulation (tACS), in particular, has shown great potential due to its unique rhythmic modulation capabilities in the treatment of neuropsychiatric disorders9,10. The tACS may resynchronize intrinsic brain rhythms, thereby modulating cognitive processes11. Studies have demonstrated that 40 Hz tACS applied to the dorsolateral prefrontal cortex (DLPFC) can improve cognitive function in patients with psychiatric disorders and has also shown beneficial effects in cognitive enhancement in healthy subjects12–15. Additionally, 40 Hz tACS has exhibited promising applications16. Despite these advances, conventional tES primarily uses a two-electrode stimulation mode, which has limitations in terms of facality. Although a 4×1 ring electrode array was proposed to enhance stimulation facality, individual variations in brain tissue morphology significantly influence the distribution of electrical currents within the brain17. Recent studies have proposed using individualized simulation models of tES and electrode optimization methods to enhance the electric field (EF) intensity in target brain regions, minimizing current spread to non-target areas18,19. Consequently, individualized 40 Hz tACS holds promise for significantly improving cognitive function in BD patients during remission. Moreover, high-frequency rTMS of the DLPFC has been reported to positively impact memory and executive function in BD patients20,21. However, the clinical efficacy of rTMS for cognitive impairments in BD was inconsistent22–24, possibly due to variability in target selection and accuracy of localization25,26. Traditional rTMS often failed to consider structural and functional differences between individuals, resulting in suboptimal stimulation outcomes and sometimes missing the abnormal target regions27. Thus, achieving precise stimulation is crucial for enhancing the efficacy of rTMS28. Stanford University introduced the SNT mode, marking the first clinical application of individualized functional connectivity-guided TMS, targeting the strongest functional connectivity points between the subgenual anterior cingulate cortex (sgACC) and DLPFC29,30. The approach improved connectivity between deeper brain regions and the DLPFC, emphasizing the critical role of neuro-navigation in achieving accurate target localization and demonstrating the potential of personalized rTMS intervention modes31. Transitioning from these single-mode brain stimulation techniques, combining tES and rTMS has been shown to potentially enhance cortical activity regulation and cognitive function32–34, although limited studies have explored the synergistic effects of combined electromagnetic stimulation on clinical outcomes35–37. The combined effects of tACS and rTMS on BD patients remain an area requiring further investigation. Additionally, target selection presents another significant challenge in neuromodulation for BD. While traditional approaches focus on structural targets, current methods are exploring the use of individual functional connectivity to identify specific targets29,38. However, results have shown that functional targets can be influenced by the processing of resting-state MRI data, leading to variability in target identification and raising questions about the stability of such methods. Furthermore, the effectiveness of interventions based on functional targets remains to be fully explored39,40. On the other hand. structural imaging studies have revealed a disrupted white matter microstructure as a potential pivotal clues in BD41,42. Several studies have indicated decreased white matter integrity, reduced fractional anisotropy (FA), and lower levels of axonal myelination, particularly in the fronto-subcortical circuits43,44. Moreover, certain frontal-cingulate white matter connections have also been identified as stimulation targets of deep brain stimulation for major depressive disorder (MDD), demonstrating their therapeutic potential45,46. These findings suggest that using white matter structural connectivity to determine stimulation targets may be an effective approach. Structural pathways are likely to facilitate the transmission of physical intervention effects, suggesting that neuromodulation based on structural connectivity could yield better outcomes compared to functional connectivity-based approaches. This study aims to introduce a novel multimodal neuro-stimulation protocol (MNS Protocol) that utilizes individualized DTI data for target localization, and combines individually optimized tACS followed by robot-assisted navigated rTMS for multimodal intervention. We conduct a double-blind randomized controlled trial to validate the effects of the novel neuro-stimulation mode on the cognitive impairment of BD patients. The findings of this research are expected to advance the field of neuromodulation therapies for cognitive impairment in BD. ## 2. Methods and Materials ### 2.1 Novel Multimodal Neuro-stimulation Protocol (MNS Protocol) As shown in Figure 1, the novel MNS Protocol is a sequential stimulation approach that combines personalized tACS and robot-assisted navigated rTMS. The personalized tACS intervention is administered at 40Hz for a duration of 30 minutes. Immediately following the tACS, neuro-navigated rTMS is performed. This protocol leverages individualized DTI data to precisely identify fiber tracts between the DLPFC and dACC, selecting the point of highest structural connectivity as the stimulation target. By optimizing stimulation parameters for both tACS and rTMS based on individual head model, the MNS Protocol aims to enhance cognitive function in BD patients by utilizing advanced neuroimaging and targeted stimulation techniques. The specific method is described as follows: ![Figure 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/07/27/2024.07.25.24311037/F1.medium.gif) [Figure 1.](http://medrxiv.org/content/early/2024/07/27/2024.07.25.24311037/F1) Figure 1. Schematic diagram of multimodal neuro-stimulation protocol. Individual DTI data are analyzed to determine the neural fiber tract density between the DLPFC and dACC. The point with the highest connectivity density is identified as the stimulation target. Using individual T1-weighted structural images, personalized induced EF models for tACS and navigated rTMS are constructed. The tACS parameters are then optimized ensuring precise and effective stimulation in the stimulation target,, followed by the application of navigated rTMS. #### 2.1.1 Target Localization Based on Individualized DTI Image For the individualized target localization based on DTI imaging, as shown in Figure 1, T1-weighted structural images and DTI data were acquired from patients and subsequently preprocessed. The detailed scanning parameters can be found in section 2.5. The processing of T1 images used Freesurfer software for automated region-of-interest segmentation, including image grayscale normalization, gray and white matter segmentation, and fine cortex segmentation using the Desikan-Killiany template. The DTI images were processed using MRtrix3 and FSL software, including image noise reduction, Gibbs artifact removal, eddy current correction, etc. Secondly, after calculating the response function and CSD fiber directional distribution function, a fiber tracking algorithm based on the second-order FOD was used to reconstruct one million fibers in the whole brain. Subsequently, the two pre-segmented regions of interest DLPFC and dorsal anterior cingulate cortex (dACC) in the T1 structural image were extracted, registered into the DTI space, the fiber bundles passing through the two regions at the same time were screened, and the fiber density in each voxel in the fiber path was calculated as a measure of the structure. An indicator of the strength of the connection. Finally, the voxel position corresponding to the highest point of structural connection strength in the individual DTI space was converted to the MNI152 (Montreal Neurological Institute) standard T1 template space after nonlinear registration as the stimulation target. #### 2.1.2 Treatment Protocol of Personalized tACS After determining the individualized stimulation target, we proceeded to optimize the treatment parameters of tACS for each patient as depicted in Figure 1. We optimize the electric field intensity and focus of the target point. While maximizing the electric field intensity in the target area, it minimizes the electric field intensity in non-target areas and improves the focus of the electric field. In addition, some current constraints are set for safety reasons, including the size limit of the total electrode current and the size limit of a single electrode current. The specific steps are as follows: First, the SIMNIBS tool software was applied for constructing individualized head models. The selected stimulation electrode employed in this study is a 10 mm diameter disc electrode. The electrical conductivity characteristics of each corresponding tissue and material set to: 0.465 S/m (scalp), 0.01 S/m (skull), 1.65 S/m (cerebrospinal fluid), 0.276 S/m (gray matter), 0.126 S/m (white matter), 2.5e-14 S/m (air cavity), 5.9e7 S/m (electrode), and 0.3 S/m (conductive paste). The proposed electrode optimization approach for tES involves the following sequential steps. Primarily, the initial step involves the calculation of the leadfield matrix, denoted as *A*: ![Formula][1] Where: ![Formula][2] *rN* represents the node position on the head model, *N* denotes the number of nodes in the head model, and *M* signifies the total number of candidate electrodes. To enhance computational efficiency, the EF intensity of the minimized non-target region is quantified as the EF intensity on the voxel point situated at a distance of 1/4* the maximum distance from the target point. The overarching objective of electrode optimization is expressed through the optimization function: ![Formula][3] where *s* denotes the magnitude of the stimulation current*, e TC* signifies the distribution of the required EF intensity at the target, and E0.25d_max denotes the EF intensity at a node located at 1/4* the maximum distance from the target point. The weight parameter *λ* is used to balance the two objectives of focality and EF intensity. Constraints condition are integral to the optimization method. Firstly, the total input current of the electrode must equal the output current, ensuring a balanced current sum. ![Formula][4] Additionally, the sum of the absolute values of the current is not larger than *Itotal*. ![Formula][5] and the absolute value of the current of a single electrode is not greater than *Imax*. ![Formula][6] for clinical applicability, constraints limiting the number of electrodes (denoted as 𝑛) are introduced:. ![Formula][7] and the absolute value of the current of a single electrode is not greater than Imax. In this study, we set the *Itotal* at 4 mA, with a maximum current *Imax* of 2 mA per electrode. The number of electrodes 𝑛 was selected to be either 4 or 5. #### 2.1.3 Treatment Protocol of Navigated rTMS In this study, we combined the acquired individual structural MRI images to construct personalized head models using SIMNIBS software. Our head models encompassed essential components such as the scalp, skull, cerebrospinal fluid (CSF), gray matter (GM), white matter (WM), and other brain tissues. The figure-of-eight coil, featuring an inner diameter of 20 mm and an outer diameter of 70 mm, was integrated into the simulation model. The coil was positioned directly above the C3 region and simulated as current sources characterized by a frequency of 3 kHz and a current amplitude of 5 kA. We conducted simulations to analyze the electric fields generated within the brain by TMS at different coil angles. The optimal coil placement angle was selected to ensure that the electric field at the target site was sufficiently large for each individual. A neuro-navigation system was employed for rTMS. Firstly, the individualized head model was co-registered with a standard brain using AC-PC alignment. The MRI images were converted into three-dimensional skin and brain models to replicate the head characteristics of patient. Using a visual localization system, a head positioning mask, and appropriate computer software, the treatment site was identified on the patient’s scalp. Subsequently, the treatment was administered by aligning the coil at the specified angle with the determined treatment site. #### 2.1.4 Sequential Personalized tACS and Navigated rTMS The MNS protocol proposed in this study represents a departure from traditional unimodal electrical or magnetic stimulation techniques. This protocol employs a dual-modal approach, combining personalized tACS with navigated rTMS. The personalized tACS intervention is administered at 40Hz for a duration of 30 minutes. Immediately following the tACS, neuro-navigated rTMS is performed. Each daily rTMS treatment consisted of 60 five-second 10-Hz trains delivered at 100% of the resting motor threshold (RMT) with inter-train intervals of 15 s (i.e., 3000 pulses per session, 45,000 pulses overall). For the sham treatment, the coil was directed to the same target with the simulation of scalp sensations with the production of the same sounds, without the application of the magnetic field. Each participant received 15 days of tACS-rTMS treatment. This sequential application is designed to maximize the synergistic effects of electromagnetic stimulation on cognitive function. ### 2.2 Trial Design As illustrated in Figure 2A, to validate the efficacy of the proposed MNS protocol, a randomized controlled double-blind clinical trial was conducted. The stringent experimental design ensures that both participants and investigators remain blinded to the treatment allocation, thereby minimizing potential biases and enhancing the validity and reliability of the findings. ![Figure 2.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/07/27/2024.07.25.24311037/F2.medium.gif) [Figure 2.](http://medrxiv.org/content/early/2024/07/27/2024.07.25.24311037/F2) Figure 2. Clinical trial design and intervention paradigm. A. Participants underwent a three-week multimodal intervention combining transcranial electrical stimulation and transcranial magnetic stimulation. Each week consisted of daily sessions, totaling 15 sessions. Cognitive assessments and imaging examinations were conducted before and after the intervention, with a cognitive follow-up assessment in the fifth week post-intervention. B. Group A received 30 minutes of Active tACS followed by 20 minutes of Active rTMS. Group B received 30 minutes of Sham tACS followed by 20 minutes of Active rTMS. Group C received 30 minutes of Active tACS and Sham rTMS. Group D received 30 minutes of Sham tACS and Sham rTMS. Each participant with recorded scores at three time points, W0: Week 0, W3: Week 3, W8: Week 8. Participants were randomly assigned to any one of the four groups: A, B, C, or D. In Group A (Active tACS and Active rTMS (MNS Protocol)), tACS is the active stimulation, and rTMS is the active stimulation group. In Group B (Sham tACS and Active rTMS), tACS is the sham stimulation, and rTMS is the active stimulation group. In Group C (Active tACS and Sham rTMS), tACS is the active stimulation, and rTMS is the sham stimulation group. In Group D (Sham tACS and Sham rTMS), both tACS and rTMS are sham stimulation. The personalized localization was conducted for the four groups of patients, All the participants were received a consecutive three-week treamtment including five times per week. As illustrated in Figure 2B, the active rTMS group received rTMS treatment at 100% RMT, while the sham stimulation group received stimulation at 20% RMT. The active tACS group underwent 30 minutes of alternating current stimulation, whereas the sham tACS group had current passing only during the initial and final 30 seconds of the stimulation. Cognitive and imaging assessments were conducted before (Week 0, W0) and after (Week 3, W3) the treatment. Psychological scale evaluations were performed during the treatment, and adverse reactions were documented. The clinical cognitive symptoms and treatment safety were evaluated, with follow-up cognitive evaluations conducted at Week 8 (W8). ### 2.3 Participants This study recruited patients with stable-phase BD and cognitive impairment from the outpatient Psychiatric Department of the First Affiliated Hospital, Zhejiang University School of Medicine, from July 2023 to February 2024. The research was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Approval number: IIT20230058C-R1). The study has been registered in the Clinical Trials Registry ([http://www.clinicaltrials.gov](http://www.clinicaltrials.gov)) with the registration number [NCT05964777](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT05964777&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F27%2F2024.07.25.24311037.atom). Before participation, all participants provided informed consent, ensuring their understanding of the objectives, procedures, and potential risks of this study. Participant confidentiality and well-being was upheld throughout the study. The inclusion criteria included, (i) Aged 14-45, regardless of gender; (ii) Diagnosis of BD in accordance with the Mini-International Neuropsychiatric Interview (M.I.N.I.); (iii) Stable medication treatment for at least three months; (iv) Clinical remission for at least 3 months before entering the randomization phase, with a Young Mania Rating Scale (YMRS) score ≤6 and Hamilton Depression Rating Scale (HAMD-17) score ≤7; (v) Cognitive impairment indicated by a Perceived Deficits Questionnaire (PDQ) score ≥17; (vi) Right-handed; (vii) Education level ≥9 years. The exclusion criteria included: (i) Comorbidities of any other mental disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); (ii) Any contraindications for MRI or the discovery of structural abnormalities in brain MRI; (iii) Pregnant, lactating women, breastfeeding or those planning to become pregnant; (iv) Patients who have undergone ECT, rTMS, or tACS treatment in the last 3 months; (v) History of serious neurologic illnesses, such as epilepsy or traumatic brain injury; (vi) Significant and unstable medical conditions, including diabetes or cardiovascular, hematological, endocrine, liver, or kidney disease; (vii) History of substance abuse and dependence, (viii) Achromatopsia, hypochromatopsia, or dysaudia; (ix) Medication with antidepressant or anticholinergic agents. ### 2.4 Imaging Imaging was conducted using a 3.0 Tesla scanner (GE SIGNA) with a standard whole-head coil at the First Affiliated Hospital, Zhejiang University School of Medicine. Participants were instructed to lie on the scanner bed with their eyes closed. Foam cushions were placed on either side of the head to minimize head motion, and ear plugs were provided to reduce noise interference. High-resolution 3D anatomical images were acquired using a T1-weighted magnetization prepared rapid acquisition gradient-echo (MPRAGE) sequence. The scanning parameters were as follows: 3D T1 structural image: TR/TE = 7.1/2.9 ms; 146 slices, slice thickness 1 mm; flip angle = 8°; matrix size = 256×256; field of view = 260×260 mm². For the DTI diffusion image, a planar echo sequence was used with the following parameters: TR/TE = 11000/89.4 ms; matrix size = 256×256; field of view = 240×240 mm²; number of slices = 44; slice thickness = 3 mm. The b value for DTI scanning was 1000 s/mm², and 25 diffusion directions were included. During scanning, participants were instructed to keep their eyes closed. To minimize head motion, foam cushions were strategically placed on either side of the head, and earplugs were utilized to mitigate noise. ### 2.5 Imaging Analysis #### 2.5.1 fMRI Analysis The fMRI data preprocessing was conducted using Data Processing Assistant for Resting-State fMRI (DPARSF) Advanced Edition V5.4 in MATLAB 2020. The key preprocessing steps included segmenting the MRI data into 10 periods, discarding the first 10 noisy time points, and synchronizing slice timing. Participants with head movement exceeding 3 mm or 3°were excluded from the analysis. Functional images were normalized to the MNI space using T1-based segmentation and registration. Spatial smoothing was applied using an 8mm×8mm×8mm Gaussian kernel. Linear drift was removed through linear regression to reduce the effects of thermal noise. Band-pass filtering (0.01-0.1Hz) was employed to eliminate physiological noise. The brain was parcellated into regions based on the AAL116 template, treating each region as a network node. Pearson correlation coefficients of the time series were computed to construct brain network matrices, which were Fisher Z-transformed for subsequent statistical analysis. Graph theory analysis was conducted using GRETNA software, calculating global and nodal metrics of the brain network matrices for both the baseline and post-treatment groups over a sparsity range of 0.01